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Online License and Registration 
Renewals 
The Iowa Board of Pharmacy has converted its legacy 
licensing database to iGov Solutions, LLC’s licensing and 
enforcement management system, also known as iLEMS. 
You may now log on to https://iowa.igovsolution.com/ 
iboponline/User_login.aspx and create a user profile. 
Through this portal, individuals can manage personal 
information online, including updating address and em-
ployment information.
A cornerstone to this system is that it allows licensees 
and registrants to renew and pay for licenses and registra-
tions online through their respective user profiles. Phar-
macists, technicians, and individual Controlled Substance 
Act (CSA) registrants are able to renew through the online 
portal. Additional license and registration categories will 
be added and given online renewal permissions throughout 
2018. Businesses, including pharmacies, will be able to 
renew licenses online starting November 1, 2018. 
Please visit the Board’s website at https://pharmacy 
.iowa.gov/licensureregistration for additional online 
services, including license verification and checking 
the status of pending applications.
PMP Data Integrity
It is vitally important that prescribers and pharmacists 
have access to complete, accurate, and current prescription 
monitoring program (PMP) data in order to continue to 
address the country’s prescription drug abuse epidemic. 
Prescribers, excluding veterinarians, are now required to 
register with the Iowa PMP at the time they renew their 
individual controlled substance (CS) registration. Manda-
tory use of the PMP will be dictated by the prescribing 
professionals’ respective licensing boards. Utilization of 
the PMP will undoubtedly increase exponentially.
The Board would like to stress that data submissions to 
the PMP must be accurate and timely. Data submissions 
must occur no later than the next business day following continued on page 4
the date of dispensing. Pharmacists need to be mindful 
that on days their pharmacy is not open or does not dis-
pense any CS prescriptions, a “zero report” must still be 
filed with the PMP.  
Pharmacists need to exercise an abundance of caution 
when updating information within the pharmacy’s prescrip-
tion dispensing software. Recently, an incident occurred 
at a pharmacy where one prescriber’s National Provider 
Identifier (NPI) number was added in error to another pro-
vider’s file within the pharmacy’s dispensing software. The 
software was programmed to update Drug Enforcement 
Administration (DEA) information based on the practitio-
ner’s NPI. Consequently, the incorrect DEA information 
was updated and all future prescriptions, including CS, 
processed under that provider contained inaccurate data. 
This inaccurate data was then submitted to the PMP.
Prescribers, pharmacists, medical examiners, law en-
forcement officials, and researchers rely on the PMP data 
around the clock. The accuracy and timeliness of the data 
submitted to the PMP by pharmacies and dispensers is of 
utmost importance.
PMP – Integrate Now!
The Board deployed Appriss Health’s PMP solution, 
PMP AWARXE, on April 4, 2018. The upgraded software 
is capable of integrating electronic health records and 
pharmacy dispensing software. Integration provides phar-
macists and their delegates with no-click access to Narx 
Scores and one-click access to full NarxCare reports within 
a matter of seconds. Interfaces are currently built for the 
following pharmacy dispensing software:
♦ Rx1/Synercom





The purpose of the Attestation Form is to document the 
candidate’s completion of required training and certain skill 
and competency assessments in such areas as aseptic 
technique, equipment cleaning, and use of personal 
protective equipment. More details about the CSPT Program 
are available on PTCB’s website at www.ptcb.org.
DEA Enables Mid-level Practitioners to 
Prescribe and Dispense Buprenorphine
In January 2018, DEA announced a deregulatory measure 
that will make it easier for residents of underserved areas to 
receive treatment for opioid addiction. Nurse practitioners 
and physician assistants can now become Drug Addiction 
Treatment Act-Waived qualifying practitioners, which gives 
them authority to prescribe and dispense the opioid main-
tenance drug buprenorphine from their offices. This final 
rule took effect January 22, 2018. More details about DEA’s 
amendments are available in a Federal Register notice titled 
“Implementation of the Provision of the Comprehensive Ad-
diction and Recovery Act of 2016 Relating to the Dispens-
ing of Narcotic Drugs for Opioid Use Disorder” (Document 
Number: 2018-01173).
New CDC Training Offers CPE on 
Antibiotic Stewardship
The Centers for Disease Control and Prevention’s (CDC’s) 
Office of Antibiotic Stewardship is offering free continuing 
education opportunities for health care professionals. 
Focused on judicious antibiotic prescribing and antibiotic 
resistance, the online training is offered in four sections, each 
with multiple modules. Section 1 of the “CDC Training on 
Antibiotic Stewardship” is open now and can be accessed at 
www.train.org/cdctrain/course/1075730/compilation. 
Additional sections will be released throughout 2018. More 
information and resources about CDC’s national effort to 
help fight antibiotic resistance and improve antibiotic 
prescribing and use are available on CDC’s website at 
www.cdc.gov/antibiotic-use/index.html. CDC is accredited 
by the Accreditation Council for Pharmacy Education 
(ACPE) as a provider of continuing pharmacy education 
(CPE). This program meets the criteria for 0.258 CEUs of 
CPE credit. The ACPE Universal Activity Number is 
0387-0000-18-031-H05-P.
Walmart to Provide Free Solution to 
Dispose of Medications With Schedule 
II Prescriptions
In partnership with Walmart, DisposeRx will provide a 
safe and easy way to neutralize unused, unwanted, or expired 
prescription opioids. DisposeRx developed a powdered prod-
uct, also called DisposeRx, that permanently dissolves when 
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DEA Launches New Tool to Help 
Distributors Make Informed Decisions 
About Customers
In February 2018, Drug Enforcement Administration 
(DEA) launched a new tool to assist drug manufacturers and 
distributors with their regulatory obligations under the Con-
trolled Substances Act. The agency added a new feature to 
its Automation of Reports and Consolidated Orders System 
(ARCOS) Online Reporting System, a comprehensive drug re-
porting system that monitors the flow of controlled substances 
(CS) from their point of manufacture through commercial 
distribution channels to the point of sale at the dispensing/
retail level. This newly added function will allow the more 
than 1,500 DEA-registered manufacturers and distributors to 
view the number of registrants who have sold a particular CS 
to a prospective customer in the last six months. 
DEA regulations require distributors to both “know their 
customer” and to develop a system to identify and report suspi-
cious orders. Manufacturers and distributors have asked DEA 
for assistance in fulfilling these obligations and have requested 
ARCOS information to help them determine if new customers 
are purchasing excessive quantities of CS. This new tool will 
provide valuable information for distributors to consider as 
part of their assessment. More details are available in a news 
release at www.dea.gov/divisions/hq/2018/hq021418.shtml.
PTCB Launches Certified Compounded 
Sterile Preparation Technician Program
In January 2018, the Pharmacy Technician Certification 
Board (PTCB) launched the PTCB Certified Compounded 
Sterile Preparation Technician (CSPT) Program. To be eligible 
to apply, a technician must:
♦ Be a PTCB certified pharmacy technician (CPhT) in
good standing; and
♦ Have completed either a PTCB-recognized sterile com-
pounding education/training program and one year of
continuous full-time compounded sterile preparation
work experience, or three years of continuous full-time
compounded sterile preparation work experience.
To earn CSPT Certification, eligible CPhTs are required 
to pass the CSPT Exam and submit competency attestation 
documentation from a qualified supervisor. The two-hour, 
75-question CSPT Exam covers  hazardous and nonhazardous 
compounded sterile products in the four domains of:
♦ Medications and components (17%);
♦ Facilities and equipment (22%);
♦ Sterile compounding procedures (53%); and
♦ Handling, packaging, storage, and disposal (8%).
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mixed with water and sequesters excess opioids and other 
drugs in a stiff, biodegradable gel that can be safely thrown 
in the trash. Walmart will provide a free packet of DisposeRx 
with every new Schedule II prescription filled at its 4,700 
pharmacies nationwide. “This partnership with DisposeRx is 
an exciting opportunity for Walmart to protect the safety of its 
customers and public health. Unwanted or expired prescrip-
tion medications left inside consumers’ medicine cabinets 
can be an easy source for those seeking to misuse or abuse a 
prescription drug,” said Pharmacy Clinical Services Manager 
for WalMart Health and Wellness and NABP Past President 
Jeanne D. Waggener, RPh, DPh. “We’re not just making it 
easy for patients to safely dispose of their medications, but 
we’re also helping prevent abuse before it starts.” Additional 
information is provided in a January 17, 2018 news release 
titled “Walmart Launches Groundbreaking Disposal Solution 
to Aid in Fight Against Opioid Abuse and Misuse.”
ASHP Research and Education 
Foundation Predicts Trends to Affect 
Pharmacy in 2018
In the 2018 Pharmacy Forecast: Strategic Planning Advice 
for Pharmacy Departments in Hospitals and Health Systems, 
the American Society of Health-System Pharmacists (ASHP) 
Research and Education Foundation provides guidance on 
eight topics that will challenge pharmacy practice leaders in 
hospitals and health systems. Published in the January 15, 
2018 issue of American  Journal of Health-System Pharmacy, 
the new report focuses on the following areas:
♦ Therapeutic innovation;
♦ Data, analytics, and technology;
♦ Business of pharmacy;
♦ Pharmacy and health-system leadership;
♦ Advanced pharmacy technician roles;
♦ Population health management;
♦ Public health imperatives; and
♦ Coping with uncertainty and chaos.
The 2018 report is available at www.ajhp.org/content/75/2/23.
USP Encourages Pharmacists to 
Help Patients Find Quality Dietary 
Supplements
Recall announcements, enforcement actions, and reports 
challenging the quality of dietary supplements are problem-
atic issues facing pharmacists who want to ensure that the 
over-the-counter (OTC) products they are recommending to 
patients are of good quality. Many consumers purchase OTC 
dietary supplements and herbal products, often assuming they 
are regulated like prescription medications. While the law 
requires pharmaceuticals to meet specific quality standards 
set by the United States Pharmacopeial Convention (USP), 
the same requirements do not apply to supplements. For this 
reason, USP has created quality standards and a verification 
process specifically for these health products. Brands display-
ing the USP Verified Mark signal to the public that “what’s 
on their label is what’s in the bottle.” Health care 
practitioners can learn more about USP’s efforts at 
www.usp.org/dietary-supplements-herbal-medicines. 
Further,,USP Dietary Supplement Verification Services 
are available to manufacturers and brands worldwide. They 
include Good Manufacturing Practice facility auditing, 
product quality control and manufacturing product 
documentation review, and product testing. Manufacturers 
that are participating in USP’s verification program for 
dietary supplements can be found at www.usp.org/
verification-services/program-participants.
New CPE Monitor Subscription Service 
Makes Licensure Compliance Easier
To help pharmacists easily monitor their CPE 
compliance, NABP partnered with the Accreditation Council for 
Pharmacy Education (ACPE) to expand CPE Monitor® by 
offering a new subscription service. Users can keep 
their free, Standard version of CPE Monitor or upgrade to 
the Plus subscription plan. Launched in April 2018, the new 
Plus plan enables pharmacists to perform a variety of 
advanced functions beyond the Standard plan, including: 
♦ Verifying how much CPE credit must be earned to satisfy
renewal requirements;
♦ Receiving alerts when a license is nearing the end of a
CPE cycle;
♦ Uploading non-ACPE credits to a licensee’s e-Profile;
♦ Viewing consolidated transcripts for each state license;
♦ Connecting to My CPD, which allows licensees to main-
tain their continuing professional development (CPD) in
one place; and
♦ Connecting to the Pharmacists’ Learning Assistance
Network, where licensees can easily search for ACPE-
approved courses.
The Plus subscription is available for an annual, renewable 
fee of $29.95, regardless of how many licenses a pharmacist 
has or adds at a later date. It is only available via 
NABP’s new mobile app. Search for NABP e-Profile in 
Google Play Store (Android) or the App Store (iPhone). 
The Standard plan is still available for free and can also be 
accessed via the app or a desktop by signing in with NABP 
e-Profile login credentials.
For more information, visit www.nabp.pharmacy/CPE.
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A pharmacy utilizing versions of these software pro-
grams may access PMP information within workflow for 
as little as $120 per pharmacy per year. Any pharmacists 
interested in integrating their pharmacy with the state’s 
PMP should contact Jennifer Tiffany at jennifer.tiffany@
iowa.gov.
Cannabidiol Oil – Can My Pharmacy  
Sell It?
The short answer? No.
There has been a multitude of confusion over the le-
gality of selling oils labeled as containing cannabidiol 
(CBD) in Iowa pharmacies. 
Various out-of-state CBD oil producers are marketing 
their products directly to pharmacies claiming they are 
legal to sell in all 50 states. These manufacturers are 
citing the “United States Farm Bill of 2014” as a legal 
means by which they may ship CBD oil containing less 
than 0.3% tetrahydrocannabinol (THC) throughout the 
country. There is a false belief held by the producers/
distributors of these products that industrial hemp can 
be grown/distributed without restrictions. The truth is, 
there are restrictions outlined in the Farm Bill, but those 
restrictions are overlooked by the producers.
The Iowa Department of Public Health (IDPH) re-
leased the “IDPH Position Statement on CBD Product 
Availability in Iowa” on August 17, 2018. Included in 
the statement are the four exceptions in Iowa in which 
natural or synthetic cannabinoid products can be legally 
used. The exceptions are:
1. The following appropriately prescribed, Food and 
Drug Administration (FDA)-approved drugs: Ma-
rinol®, Syndros®, Cesamet®
2. Epidiolex®, produced by GW Pharmaceuticals, 
which has been approved by FDA but is awaiting 
action by DEA
3. Sativex®, produced by GW Pharmaceuticals, as part 
of an FDA-approved clinical trial
4. Products produced and approved pursuant to Iowa 
Code Chapter 124E, the Medical Cannabidiol Act, 
that contain less than 3% THC and are in a form 
recommended by the Medical Cannabidiol Board, 
approved by the Iowa Board of Medicine, and ad-
opted by the IDPH pursuant to administrative rule 
(see 641—154.14(124E) for the approved forms).
Products manufactured in the state under the provi-
sions of Iowa Code Chapter 124E will be available at 
IDPH-licensed dispensaries only, starting in late 2018.
The Iowa CSA, also known as Iowa Code Chapter 
124, mirrors the federal CSA and classifies marijuana as a 
Schedule I CS, and defines marijuana in the following way:
“Marijuana” means all parts of the plants of the 
genus Cannabis (this includes hemp), whether 
growing or not; the seeds thereof; the resin 
extracted from any part of the plant; and every 
compound, manufacture, salt, derivative, mix-
ture or preparation of the plant, its seeds or resin, 
including tetrahydrocannabinols. It does not 
include the mature stalks of the plant, fiber pro-
duced from the stalks, oil or cake made from the 
seeds of the plant, any other compound, manu-
facture, salt derivative, mixture, or preparation 
of the mature stalks (except the resin extracted 
therefrom), fiber, oil or cake or the sterilized seed 
of the plant which is incapable of germination.
The following is an excerpt from a DEA write-up called 
“Clarification of the New Drug Code (7350) for Marijuana 
Extract,” which lays out which parts of the cannabis plant 
cannabinoids are found in, and which parts of  the cannabis 
plants are legally defined as marijuana:
. . . scientific literature indicates, cannabinoids, 
such as tetrahydrocannabinols (THC), canna-
binols, and CBD, are found in the parts of the 
cannabis plant that fall within the federal and 
state CSA definition of marijuana,[1] such as the 
flowering tops, resin, and leaves.2 According to 
the scientific literature, cannabinoids are not 
found in the parts of the cannabis plant that are 
excluded from the CSA definition of marijuana, 
except for trace amounts (typically, only parts 
per million)3 that may be found where small 
quantities of resin adhere to the surface of seeds 
and mature stalk.4 Thus, based on the scientific 
literature, it is not practical to produce extracts 
that contain more than trace amounts of can-
nabinoids using only the parts of the cannabis 
plant that are excluded from the CSA definition 
of marijuana, such as oil from the seeds. The 
industrial processes used to clean cannabis 
seeds and produce seed oil would likely further 
diminish any trace amounts of cannabinoids 
that end up in the finished product. However, 
as indicated above, if a product, such as oil 
from cannabis seeds, consisted solely of parts 
of the cannabis plant excluded from the CSA 
definition of marijuana, such product would 
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not be included in the new drug code (7350) 
or in the drug code for marijuana (7360), even 
if it contained trace amounts of cannabinoids.5
1. The CSA states: “The term ‘marihuana’ 
means all parts of the plant Cannabis sativa 
L., whether growing or not; the seeds thereof; 
the resin extracted from any part of such plant; 
and every compound, manufacture, salt, de-
rivative, mixture, or preparation of such plant, 
its seeds or resin. Such term does not include 
the mature stalks of such plant, fiber produced 
from such stalks, oil or cake made from the 
seeds of such plant, any other compound, 
manufacture, salt, derivative, mixture, or 
preparation of such mature stalks (except the 
resin extracted therefrom), fiber, oil, or cake, 
or the sterilized seed of such plant which is in-
capable of germination.” 21 U.S.C. § 802(16).
2. H. Mölleken and H. Hussman. Cannabinoid 
in seed extracts of Cannabis sativa culti-
vars. J. Int. Hemp Assoc. 4(2): 73-79 (1997).
3. See id.; see also S. Ross et al., GC-MS 
Analysis of the Total Δ9-THC Content of 
Both Drug- and Fiber-Type Cannabis Seeds, 
J. Anal. Toxic., Vol. 24, 715-717 (2000).
4. H. Mölleken, supra.
5. Nor would such a product be included under 
drug code 7370 (tetrahydrocannabinols). See 
Hemp Industries Association v. DEA, 357 F.3d 
1012 (9th Cir. 2004) (Hemp II). However, as 
the Ninth Circuit stated in Hemp II, “when 
Congress excluded from the definition of 
marijuana ‘mature stalks of such plant, fiber 
. . . , [and] oil or cake made from the seeds,’ it 
also made an exception to the exception, and 
included ‘resin extracted from’ the excepted 
parts of the plant in the definition of mari-
juana, despite the stalks and seed exception.” 
Id. at 1018. Thus, if an extract of cannabinoids 
were produced using extracted resin from 
any part of the cannabis plant (including 
the parts excluded from the CSA definition 
of marijuana), such an extract would be in-
cluded in the CSA definition of marijuana.
Based on the cited literature, products purporting to be 
CBD oil that are being offered for sale over-the-counter 
are either derived from portions of the plants in the genus 
Cannabis prohibited under the CSA (ie, the resin), or the 
products are most likely misbranded as defined by FDA.   
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